Unsere Publikationen

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Link
https://doi.org/10.1177/11795735241296001
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Schreiber H, Penner I-K, Maier T, Hieke-Schulz S, Leemhuis J, Ziemssen T.
Verlag
Journal of Central Nervous System Disease. 2024;16.
Zum Eintrag

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Link
https://doi.org/10.1212/wnl.0000000000209888
Tags
MS BehandlungAndere
Jahr
2024
Autoren
Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, Revie L, Giglhuber K, Häußler V, Karenfort M, Hellwig K, Paul F, Bellmann-Strobl J, Otto C, Ruprecht K, Ziemssen T, Emmer A, Rothhammer V, Nickel FT, Angstwurm K, Linker R, Laurent SA, Warnke C, Jarius S, Korporal-Kuhnke M, Wildemann B, Wolff S, Seipelt M, Yalachkov Y, Retzlaff N, Zettl UK, Rommer PS, Kowarik MC, Wickel J, Geis C, Hümmert MW, Trebst C, Senel M, Gold R, Klotz L, Kleinschnitz C, Meuth SG, Aktas O, Berthele A, Ayzenberg I; German Neuromyelitis Optica Study Group (NEMOS).
Verlag
Neurology. 2024 Nov 12;103(9):e209888.
Zum Eintrag

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Link
https://doi.org/10.57264/cer-2023-0161
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
Verlag
J Comp Eff Res. 2024 Aug 19:e230161.
Zum Eintrag

Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER

Link
https://doi.org/10.1016/j.msard.2024.105812
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Ziemssen T, Posevitz-Fejfár A, Chudecka A, Cepek L, Reifschneider G, Grothe C, Richter J, Wagner T, Müller B, Penner IK.
Verlag
Mult Scler Relat Disord. 2024 Aug 10;90:105812.
Zum Eintrag

Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA

Link
https://doi.org/10.1016/j.nerep.2024.100211
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Yalachkov Y, Akgün K, Ziemssen T.
Verlag
Neuroimmunology Reports. 2024, 5:100211.
Zum Eintrag

Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis

Link
https://doi.org/10.1016/j.msard.2024.105751
Tags
Multiple SkleroseMS BehandlungManagement & Science
Jahr
2024
Autoren
Papukchieva S, Kim HD, Stratil AS, Magurne E, Jonckheere A, Kahn M, Schneeweiss S, Ziemssen T, Friedrich B.
Verlag
Mult Scler Relat Disord. 2024 Jul 4;88:105751.
Zum Eintrag

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Link
https://doi.org/10.3389/fimmu.2024.1404316
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Höpner L, Proschmann U, Inojosa H, Ziemssen T, Akgün K.
Verlag
Front Immunol. 2024 Jun 13;15:1404316.
Zum Eintrag

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Link
https://doi.org/10.1007/s40120-024-00637-2
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Singer BA, Wray S, Gudesblatt M, Bumstead B, Ziemssen T, Bonnell A, Scaramozza M, Levin S, Shanmugasundaram M, Chen H, Mendoza JP, Lewin JB, Shankar SL.
Verlag
Neurol Ther. 2024 Jun 27.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-